Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Angiotensin-Converting Enzyme 2
-
Animals
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Neutralizing / chemistry
-
Antibodies, Neutralizing / immunology*
-
Antibodies, Neutralizing / pharmacology
-
Antibodies, Viral / chemistry
-
Antibodies, Viral / immunology
-
Antibodies, Viral / pharmacology
-
Antibody-Dependent Cell Cytotoxicity / drug effects
-
Antibody-Dependent Cell Cytotoxicity / immunology
-
B-Lymphocytes / immunology
-
Betacoronavirus / chemistry
-
Betacoronavirus / drug effects
-
Betacoronavirus / immunology*
-
COVID-19
-
Chlorocebus aethiops
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control
-
Coronavirus Infections / therapy
-
Coronavirus Infections / virology
-
Cross Reactions / drug effects
-
Cross Reactions / immunology*
-
Cryoelectron Microscopy
-
Epitopes, B-Lymphocyte / chemistry
-
Epitopes, B-Lymphocyte / immunology
-
HEK293 Cells
-
Humans
-
Immune Evasion / immunology
-
Immunoglobulin Fab Fragments / chemistry
-
Immunoglobulin Fab Fragments / immunology
-
Immunoglobulin Fab Fragments / pharmacology
-
Immunologic Memory / immunology
-
Killer Cells, Natural / drug effects
-
Killer Cells, Natural / immunology
-
Models, Molecular
-
Neutralization Tests
-
Pandemics / prevention & control
-
Peptidyl-Dipeptidase A / chemistry
-
Peptidyl-Dipeptidase A / metabolism
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / prevention & control
-
Pneumonia, Viral / therapy
-
Pneumonia, Viral / virology
-
SARS-CoV-2
-
Severe Acute Respiratory Syndrome / immunology*
-
Severe Acute Respiratory Syndrome / virology
-
Severe acute respiratory syndrome-related coronavirus / chemistry
-
Severe acute respiratory syndrome-related coronavirus / drug effects
-
Severe acute respiratory syndrome-related coronavirus / immunology*
-
Spike Glycoprotein, Coronavirus / chemistry
-
Spike Glycoprotein, Coronavirus / immunology*
-
Vero Cells
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Epitopes, B-Lymphocyte
-
Immunoglobulin Fab Fragments
-
Spike Glycoprotein, Coronavirus
-
spike protein, SARS-CoV-2
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2